Compare Home Depot Inc (HD) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Home Depot Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Home Depot Inc trades at $294.5 (market cap $294.79B), while State Street SPDR S&P Biotech ETF trades at $149.89 (market cap $10.11B). The key difference: Home Depot Inc is far larger — about 29.2× State Street SPDR S&P Biotech ETF's market cap, and Home Depot Inc pays a 3.15% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Home Depot Inc for 139 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| HD | XBI | |
|---|---|---|
Market Cap | $294.79B | $10.11B |
Volume | 8,693,917 | 12,903,266 |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $391.90 | $169.55 |
52-Week Low | $281.15 | $104.99 |
Typical Hold Time | 139 Days | 37 Days |
Enterprise Value | $355.27B | — |
Dividend Yield | 3.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Home Depot (HD) trades at $285.77, down 0.32% on the day, with a bearish technical signal despite strong analyst support. The stock shows consistent earnings beats in recent quarters with Q2 2026 EPS of $4.92 exceeding expectations. Revenue reached $159.51B in 2025, though profit margins have declined from 10.87% in 2022 to 9.28% currently. Institutional activity shows mixed positioning with some funds increasing while others reducing holdings.
The stock presents a compelling value opportunity with a consensus price target of $379.93 representing 33% upside potential. However, weakening profit margins, rising mortgage rates impacting housing demand, and bearish technical indicators create near-term headwinds. Long-term prospects remain supported by professional segment growth and housing market tailwinds.
XBI trades at $150.23, down 0.44% on the day, with a bearish technical signal driven by moving averages and oscillators. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts. Recent news highlights sector optimism from cancer vaccine breakthroughs and improved capital access, though the ETF carries higher volatility than broader healthcare funds.
The outlook is mixed: strong sector tailwinds from innovation and consolidation support growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst sentiment is neutral with 100% hold ratings, suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Home Depot Inc
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
